Diazoxide for treating type 1 glycogenosis
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests whether a medicine called diazoxide can help treat type 1 glycogenosis, a rare metabolic condition that affects how the body stores and uses sugar. Participation is limited to patients already being followed at one of two French hospitals.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be diagnosed with type 1 glycogen storage disease and be followed at the CHRU de Nancy or CHU de Besançon hospitals in France.
- You must have given permission for your medical data to be used in this study (or a parent or guardian must consent if you are a minor).
- Your medical records must contain enough information to meet the study's goals.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different diet strategies to help adults with GSDI (a metabolic condition also known as von Gierke disease) maintain stable blood sugars and avoid dangerous drops. It may help you learn how to better manage your condition through diet.
This study tests whether a carbohydrate counting method helps children with glycogen storage disease type 1 (GSD1) better manage their blood sugar, improve quality of life, and affect certain biomarkers. It may help families learn a new way to plan meals and stabilize glucose levels.
This study tests how well a home lactate meter and a standard blood sugar meter work for people with certain types of Glycogen Storage Disease (GSD Ia, Ib, or XI). If you or your child has one of these types, joining could help improve home monitoring.
This study tracks the health of people with type 3 Glycogen storage disease. It may help doctors understand the disease better and plan better care.
This study tests an experimental medicine called BEAM-301 for people with a specific form of glycogen storage disease type Ia (GSDIa). The goal is to see if it can help reduce dangerous low blood sugar episodes.
This Phase 2 study tests how certain channels in the brain help control how your body makes and releases sugar (glucose). It may help explain blood sugar problems in people with type 2 diabetes and healthy volunteers.
Hear when a new Glycogen Storage Disease Type I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.